Cardiovascular Manifestation In Moderate ToSevere COVID-19 Patients Undergoing Treatment InCritical Care Unit Of A Tertiary Care Hospital,West Bengal And Role Of Portable, Point Of CareCardiac Biomarker Autoanalyzer In Their EarlyDiagnosis.

开始日期2021-07-01

申办/合作机构

Kolkata Medical College

100 项与 Kolkata Medical College 相关的临床结果

登录后查看更多信息

0 项与 Kolkata Medical College 相关的专利（医药）

登录后查看更多信息

697

项与 Kolkata Medical College 相关的文献（医药）

2024-06-01·Cardiology and Therapy

Management of Heart Failure in a Resource-Limited Setting: Expert Opinion from India

Review

作者: Sharma, Kamal ; Guha, Santanu ; Kotak, Bhavesh ; Kumar, Soumitra ; Dhediya, Rajnish ; Gaurav, Kumar ; Jain, Peeyush ; Sureshkumar, K P ; Mittal, Rajan ; Mehta, Ashwani ; Sawhney, J P S

Heart failure poses a global health challenge affecting millions of individuals, and access to guideline-directed medical therapy is often limited. This limitation is frequently attributed to factors such as drug availability, slow adoption, clinical inertia, and delayed diagnosis. Despite international recommendations promoting the use of guideline-directed medical therapy for heart failure management, personalized approaches are essential in settings with resource constraints. In India, crucial treatments like angiotensin II receptor blocker neprilysin inhibitors and sodium-glucose co-transporter 2 inhibitors are not fully utilized despite their established safety and efficacy. To address this issue, an expert consensus involving 150 specialists, including cardiologists, nephrologists, and endocrinologists, was convened. They deliberated on patient profiles, monitoring, and adverse side effects and provided tailored recommendations for guideline-directed medical therapy in heart failure management. Stressing the significance of early initiation of guideline-directed medical therapy in patients with heart failure, especially with sodium-glucose co-transporter 2 inhibitors, the consensus also explored innovative therapies like vericiguat. To improve heart failure outcomes in resource-limited settings, the experts proposed several measures, including enhanced patient education, cardiac rehabilitation, improved drug access, and reforms in healthcare policies.

2024-06-01·Current Problems in Cardiology

Association between psoriasis and atrial fibrillation: A Systematic review and meta-analysis

Review

作者: Odat, Ramez M ; Gole, Shrey ; Dey, Debankur ; Goyal, Aman ; Jain, Hritvik ; Passey, Siddhant ; Ahmed, Mushood ; Wasir, Amanpreet Singh ; Jain, Jyoti

INTRODUCTIONPsoriasis is a prevalent inflammatory skin condition characterized by erythematous plaques with scaling. Recent research has demonstrated an increased risk of cardiovascular diseases in patients with psoriasis; however, current evidence on atrial fibrillation (AF) risk in psoriasis is limited.MATERIALS AND METHODSA systematic literature search was performed on major bibliographic databases to retrieve studies that evaluated AF risk in patients with psoriasis. The DerSimonian and Laird random effects model was used to pool the hazard ratios (HR) with 95 % confidence intervals (CI). Subgroup analysis was conducted by dividing the patients into mild and severe psoriasis groups. Publication bias was assessed by visual inspection and Egger's regression test. Statistical significance was set at p < 0.05.RESULTSSeven studies were included, with 10,974,668 participants (1,94,230 in the psoriasis group and 10,780,439 in the control group). Patients with psoriasis had a significantly higher risk of AF [Pooled HR: 1.28; 95 % CI: 1.20, 1.36; p < 0.00001]. In subgroup analysis, patients with severe psoriasis [HR: 1.32; 95 % CI: 1.23, 1.42; p < 0.00001] demonstrated a slightly higher risk of AF, although statistically insignificant (p = 0.17), than the mild psoriasis group [HR: 1.21; 95 % CI: 1.10, 1.33; p < 0.0001]. Egger's regression test showed no statistically significant publication bias (p = 0.24).CONCLUSIONOur analysis demonstrated that patients with psoriasis are at a significantly higher risk of AF and hence should be closely monitored for AF. Further large-scale and multicenter randomized trials are warranted to validate the robustness of our findings.

2024-04-12·Cureus

Evaluating the Efficacy, Safety, and Tolerability of Combination Therapy of Dapagliflozin and Linagliptin Over Dapagliflozin and Vildagliptin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

Article

作者: Chakraborty, Sisir ; Kumar, Ritesh ; Bachubhai, Prajapati Vipul Kumar ; Kumar Manjunath, Krishna ; Maiti, Animesh ; Ogale, Dhananjay ; Sonawane, Ashutosh B ; Prakash, Ved ; Shah, Vaishal ; Kumar Sharma, Surendra ; Dharmalingam, Mala ; Maheshwari, Sanjiv ; Naik Kethavath, Sunil ; Suresh, Manjula ; Ramanathan, Balamurugan ; Murthy, Laxminarayanappa Sreenivasa S

Background Type 2 diabetes mellitus (T2DM) patients commonly undergo metformin monotherapy. This study aims to compare the efficacy, safety, and tolerability of combination therapy of dapagliflozin plus linagliptin versus dapagliflozin plus vildagliptin as add-on therapy in T2DM patients inadequately controlled on metformin. Methodology This was an 18-week, multicenter, randomized, double-blind, active-controlled, parallel-group, phase III clinical study. About 236 participants were randomly assigned to receive either a fixed-dose combination of dapagliflozin 10 mg plus linagliptin 5 mg tablets or a fixed-dose combination of dapagliflozin 10 mg plus vildagliptin SR 100 mg tablets added to metformin monotherapy. The primary outcome was the mean change in hemoglobin A1c (HbA1c) from baseline to the end of week 16. The key secondary endpoints were mean change in postprandial blood glucose (PPBG), fasting blood glucose (FBG), body weight, and the proportion of participants achieving HbA1c less than 7.0%. Results The dapagliflozin/linagliptin combination therapy showed a more significant change in HbA1c from baseline to the end of 16 weeks (mean reduction: -1.59% vs. -1.25%) compared to dapagliflozin/vildagliptin (p < 0.0001). Additionally, compared to the dapagliflozin/vildagliptin group, the dapagliflozin/linagliptin group demonstrated a significant reduction in both PPBG (mean reduction: -59.99 mg/dL vs. -55.34 mg/dL) and FPG (mean reduction: -32.91 mg/dL vs. -26.78 mg/dL). A total of 18 adverse events were reported in 17 (7.20%) participants, all of which were mild and resolved completely. There were no serious adverse events. Conclusions Compared to dapagliflozin and vildagliptin combination therapy, dapagliflozin and linagliptin fixed-dose combination provided clinically significant improvements in glycemic control. Because of its effectiveness, safety, and tolerability, the fixed-dose combination of dapagliflozin and linagliptin was a better option for treating T2DM patients who had previously only received metformin monotherapy.

100 项与 Kolkata Medical College 相关的药物交易

登录后查看更多信息

100 项与 Kolkata Medical College 相关的转化医学

登录后查看更多信息